All Eyes on High-Dose Eylea as Roche’s New Vabysmo Makes Moderate Impact in Blockbuster Eye Disease Market
Roche’s Vabysmo is making inroads into the wet AMD eye disease market, but Regeneron’s behemoth Eylea is holding its own, and a new, higher dose version may further entrench Eylea. That’s according to the latest survey of 110 ophthalmologists from healthcare research consultants at Spherix. While ophthalmologists initially thought most Vabysmo uptake to be at the expense of […]
Spherix Analyzes Reviews of gMG Therapies, Vyvgart, Ultomiris
Neurologists find both Vyvgart (efgartigimod) and Ultomiris (ravulizumab-cwvz) effective for treating generalized myasthenia gravis (gMG), but believe Ultomiris has a more convenient dosing schedule while Vyvgart may have a better safety profile. That’s according to a recent analysis by the market intelligence firm Spherix Global Insights. Spherix’s analysis of the two treatments was part of Launch Dynamix, a service that provides […]
Genentech’s Vabysmo Slowly Chips Away at Competition in the Neovascular (Wet) AMD Market While Regeneron’s Eylea Holds its Ground (For Now), According to New Spherix Report
Newer ranibizumab entrants, Byooviz (Samsung/Biogen) and Susvimo (Genentech), struggle to make an impact EXTON, Pa., September 1, 2022 /PRNewswire/ – Since the FDA approval in January this year, ophthalmologists have been very optimistic about their intended use of Genentech’s Vabysmo (faricimab-svoa) for the treatment of neovascular (wet) age-related macular degeneration (nAMD). The latest quarterly report […]
Argenx’s Vyvgart and Alexion’s Ultomiris Go Toe-to-Toe in Generalized Myasthenia Gravis, According to Spherix Global Insights
Positive perceptions for both brands will drive expansion of patient share and prescriber base EXTON, Pa., August 24, 2022/ PRNewswire/ – Competition in the generalized myasthenia gravis (gMG) market is heating up with the launches of argenx’s Vyvgart and Alexion’s Ultomiris earlier this year. Both brands have the same approved indication but differ on mechanism […]
New IBD Mechanisms of Action Are Poised to Gain EU5 Patient Switches as Anti-TNF Therapy Efficacy Fades in Ulcerative Colitis and Crohn’s Disease, According to Spherix Global Insights
AbbVie’s Rinvoq is primed for breakout switching opportunities in the EU5 UC market with its approval by the EMA EXTON, Pa., August 12, 2022 /PRNewswire/ — According to the latest report published as part of Spherix’s RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (EU) service, EU gastroenterologists (n=285) have accelerated their switching of ulcerative colitis (UC) and Crohn’s […]
Primary Care Providers Report a High Unmet Need for New Therapeutic Treatment Options for Chronic Kidney Disease, Despite Earlier Intervention and Referrals to Nephrologists, Spherix Reports
Spherix’s third bi-annual audit analyzed the charts of 1,002 CKD non-dialysis patients with moderate to severe kidney disease treated by primary care physicians EXTON, Pa., July 9, 2021 /PRNewswire./ – Approximately 37 million Americans have chronic kidney disease (CKD)—that is one out of every seven U.S. adults.1 Many of these patients are being managed by […]
Gastroenterologists’ Urgency in Treating Celiac Disease Increases as the Number of Viable Pipeline Candidates Dwindles, According to Spherix Global Insights
The recent loss of the only Phase 3 CeD pipeline candidate highlights the unmet need of suitable treatments for a patient population seeking alternatives to the gluten-free diet EXTON, Pa., August 8, 2022 /PRNewswire/ — Spherix recently surveyed 100 US gastroenterologists and conducted eight qualitative interviews to assess the current and future management of celiac disease (CeD). […]
New Research from Spherix Finds Increased Use of SGLT2 Inhibitors Across the EU5, Including AstraZeneca’s Forxiga (Farxiga in US), in the Management of IgA Nephropathy Patients
Release of second annual EU5 research on IgA nephropathy highlights unmet needs, regional diagnosis and treatment trends, and awareness of pipeline treatments, including the availability newly approved Calliditas’ Kinpeygo EXTON, Pa., August 3, 2022 /PRNewswire/ — Glomerulonephritis is a major contributor of end-stage renal disease across the globe, with IgA nephropathy (IgAN), also known as […]
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk’s Semaglutide
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk’s Semaglutide Differentiation amongst these pipeline agents will hinge on ease of access, easy-to-use companion diagnostics, and safety EXTON, Pa., July 2022 – Despite multiple high-profile trial failures in early Alzheimer’s disease […]
Jyseleca and Zeposia: The Future of Ulcerative Colitis in the EU?
Spherix’s Eric John reveals preliminary data on two new oral agents and how they are impacting the ulcerative colitis market in the European Union. The Difficulties of Approving Therapies in Gastroenterology Did you know that ulcerative colitis patients are often the last patients to receive access to therapies approved for other immune indications? There […]
